Diana Escolar

Chief Medical Officer at Miragen Therapeutics, Inc.

Diana Escolar

Diana Escolar

Chief Medical Officer at Miragen Therapeutics, Inc.

Biography

On December 11, 2019, the Company announced that it has promoted Diana Escolar, M.D. to Chief Medical Officer. Dr. Escolar joined the Company in January 2018 and has served as its Senior Vice President of Clinical Sciences.

Overview
RelSci Relationships

6

Relationships
RelSci Relationships are individuals Diana Escolar likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Akashi Therapeutics, Inc.

Relationship likelihood: Average

Co-Founder at Novu LLC

Relationship likelihood: Average

Chief Executive Officer at Akashi Therapeutics, Inc.

Relationship likelihood: Average

Executive Vice President, Portfolio Management & Operations at Akashi Therapeutics, Inc.

Relationship likelihood: Average

Executive Chairman at ProMIS Neurosciences, Inc.

Relationship likelihood: Average

Head of Pharmacology/Toxicology at ProMIS Neurosciences, Inc.

Relationship likelihood: Weak

Paths to Diana Escolar
Potential Connections via
Relationship Science
You
Diana Escolar
Chief Medical Officer at Miragen Therapeutics, Inc.
Career History
Chief Medical Officer
Current

Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

Chief Medical Officer
Prior

Akashi Therapeutics formerly known as Dart Therapeutics Inc. Akashi Therapeutics is a clinical stage biopharmaceutical company. Our mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition.

Other Affiliations

Diana Escolar is affiliated with Miragen Therapeutics, Inc., Akashi Therapeutics, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Diana Escolar. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Diana Escolar's profile does not indicate a business or promotional relationship of any kind between RelSci and Diana Escolar.